Estimating the number of Chinese cancer patients eligible for and benefit from immune checkpoint inhibitors  

作　　者：Kaili Yang Jiarui Li Lin Zhao Zhao Sun Chunmei Bai 

机构地区：[1]Department of Medical Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100032,China

出　　处：《Frontiers of Medicine》2022年第5期773-783,共11页医学前沿（英文版）

基　　金：This work was supported by the National Natural Science Foundation of China(No.61435001);CAMS Innovation Fund for Medical Sciences(Nos.2017-I2M-4-003 and 2016-I2M-1-001).

摘　　要：The total number of cancer patients who are eligible for and will benefit from immune checkpoint inhibitors(ICIs)in China has not been quantified.This cross-sectional study was conducted to estimate the number of Chinese cancer patients with eligibility and response to ICIs based on the 2015 Chinese cancer statistics and the immune checkpoint inhibitor clinical practice guideline of the Chinese Society of Clinical Oncology.A total of 11 ICIs were recommended for 17 cancer types.The estimated number of eligible patients annually was 1290156(55.18%),which included 888738 males(60.05%)and 400468 females(46.67%).The estimated number of responders annually was 448972(19.20%),which included 309023 males(20.88%)and 139764 females(16.29%).Gastric cancer(n=291000,12.45%),non-small-cell lung cancer(n=289629,12.39%),and hepatocellular carcinoma(n=277100,11.85%)were the top three cancer types with the highest number of eligible patients.Non-small-cell lung cancer(n=180022,7.70%),hepatocellular carcinoma(n=75648,3.24%),and small-cell lung cancer(n=64362,2.75%)were the top three cancer types with the highest number of responders.In conclusion,ICIs provide considerable benefit in Chinese cancer patients under optimal estimation.

关 键 词：BENEFIT China ELIGIBILITY immune checkpoint inhibitor public health 

分 类 号：R730.5[医药卫生—肿瘤]